This approval follows the generic version of Byetta (another GLP-1) in November
Los medicamentos GLP-1 que se utilizan para tratar la obesidad estn actualmente aprobados para la prdida de peso en adultos con un IMC de 30 o ms o un IMC de 27 o ms en aquellos que tambin tienen problemas mdicos relacionados con el peso
Regular follow-up appointments allow for assessment of glycemic control (A1C monitoring every 3-6 months), weight trends, and adjustment of tirzepatide dosing as needed
This article delves into the science behind weight loss medications and bariatric surgery, exploring their benefits, limitations, and how they can fit into your personalized weight loss journey
Before your appointment, it may be helpful to track your symptoms : document when fatigue occurs, its severity, associated symptoms, dietary intake, and any patterns you notice